Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China
This trial is main evaluate the efficacy and safety of pembrolizumab in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma with PD-L1 CPS≥20.
Head and Neck Squamous Cell Carcinoma
DRUG: Pembrolizumab
Objective response rate (ORR), To evaluate the objective response rate (ORR, RECIST standard 1.1 evaluation) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20, 1 year|survival time (OS), To evaluate the survival time (OS) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20, 1year
objective response rate(ORR), To evaluate the objective response rate of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 (ORR, iRECIST standard evaluation), 1 year|disease control rate (DCR), To evaluate the disease control rate (DCR) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20, 1 year|duration of response (DOR), To evaluate the duration of response (DOR) of pembrolizumab in the first-line treatment of Chinese patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS ≥ 20, 1 year|progression-free survival (PFS, PFS2), To evaluate the progression-free survival (PFS, PFS2) of patients with recurrent and or metastatic head and neck squamous cell carcinoma with PDL1 CPS ≥ 20 in the first-line treatment of Pembrolizumab;, 1 year
TMB, T cell gene expression, Correlation between the results of TMB and inflammatory T cell gene expression profiles in tumor tissues of baseline patients and the efficacy and prognosis., 3 year
This trial is a single-center, prospective phase II clinical study, which mainly evaluates the efficacy and safety of first-line treatment with pembrolizumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma with PDL1 CPS≥20 in China.